Axcellant is excited to announce our participation at the European Association of Nuclear Medicine (EANM) Congress in Hamburg from October…
Marking a significant achievement in our ongoing efforts to advance medical device research, we have successfully concluded a PMCF study…
Initiating a clinical trial is akin to embarking on a voyage of discovery in the realm of medicine. This journey,…
Our team at Axcellant is proud to announce the completion of a significant Post-Market Clinical Follow-up study. This study was…
In the ever-evolving realm of pharmaceuticals and healthcare, a remarkable transformation is afoot - one that's reshaping the way we…
Clinical research is a complex and multifaceted field that relies on the dedicated efforts of a diverse team to bring…
Meet our team at top Nuclear Medicine Event – SNMMI in Chicago, 24 - 27 June 2023.
Regulators in the European Union (EU) have taken several initiatives in the past four years to increase the efficiency of paediatric regulatory processes and boost the development of medicines for children.
From 31 January 2023, all initial clinical trial applications in the European Union (EU) must be submitted via the Clinical Trials Information System (CTIS).
The European Commission (EC), the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published recommendations that aim to...
Copyright @ 2024 Axcellant. Designed By Frantic